Effect of Sacubattril Valsartan Sodium Combined with Recombinant Human Brain Natriuretic Peptide in the Treatment of Coronary Heart Disease with Heart Failure
Objective To observe the effect of sacubattril valsartan sodium combined with recombinant human brain natriuretic peptide(rhBNP)in patients with coronary heart disease with heart failure(HF).Methods A total of 95 patients with coronary heart disease with HF admitted to Huantai Holy Hospital in Zibo City from May 2021 to May 2023 were selected as the research subjects,randomly divided into a control group(n=47)and an observation group(n=48)according to random number table method.The control group was treated with sakubactril valsartan sodium,and the observation group was treated with sakubactril valsartan sodium combined with rhBNP.The clinical efficacy,cardiac function,serological indexes,exercise endurance and the occurrence of adverse reactions were compared between the two groups.Results The total effective rate of the observation group was 95.83%,which was higher than 76.60%of the control group,the difference was statistically significant(P＜0.05).Before treatment,there were no significant differences Cardiac Index(CI),left ventricular ejection fraction(LVEF),stroke volume(SV),cardiac output(CO)between the two groups(P＞0.05);after 4 weeks of treatment,the levels of LVEF,CI in the observation group were higher than those in the control group,the SV and CO in the observation group were more than those in the control group,and the differences between the groups were statistically significant(P＜0.05).Before treatment,there were no significant differences in serum cardiac anchor repeat protein(CARP),Aldosterone(ALD),intercellular adhesion molecule-1(ICAM-1),mitochondrial coupling factor 6(CF6)between the two groups(P＞0.05);after 4 weeks of treatment,the levels of CARP,ICAM-1,ALD and CF6 in the observation group were lower than those in the control group,and the differences between the groups were statistically significant(P＜0.05).Before treatment,there were no significant differences in maximum oxygen intake(VO2max),6 min walking distance(6MWD)between the two groups(P＞0.05);after 4 weeks of treatment,the levels of VO2max in the observation group was higher than that in the control group,the 6MWD in the observation group were significantly longer than that in the control group,and the differences between the groups were statistically significant(P＜0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P＞0.05).Conclusion Sakubactril valsartan sodium combined with rhBNP has a significant effect in the treatment of coronary heart disease with HF,which can effectively improve the cardiac function of patients,adjust the levels of serological indicator,improve exercise endurance,and has good safety.
Coronary heart diseaseHeart failureSakubactril valsartan sodiumRecombinant human brain natriuretic peptide
NETL
NSTL
万方数据
